Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 42

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 42
---
 or warrants for the purposes of computing the percentage
of beneficial ownership of that person and any group of which that person is a member, but are not deemed outstanding for the purpose
of computing the percentage of beneficial ownership for any other person. Unless otherwise indicated, the address for each holder listed
below is Biodexa Pharmaceuticals plc, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom. All holders of Ordinary Shares,
including those shareholders listed below, have the same voting rights with respect to such shares.

| Name of Beneficial Owner                                    |     | Amount and Nature 
 Of Ownership      |               |     | Percent  
 of Class |     |   |
| Major Shareholders                                          |     |                   |               |     |          |     |   |
| Entities Affiliated with Bigger Funds (1)**                 |     |                   | 1,722,030,000 |     |          | 6.7 | % |
| Entities Affiliated With Calvary Funds (2)**                |     |                   | 1,669,850,000 |     |          | 6.1 | % |
| Directors and Senior Management:                            |     |                   |               |     |          |     |   |
| Ann Merchant (3)                                            |     |                   |     9,000,000 |     |          |   * |   |
| Stephen Parker (4)                                          |     |                   |    18,000,000 |     |          |   * |   |
| Stephen Stamp (5)                                           |     |                   |    26,890,563 |     |          |   * |   |
| Simon Turton (6)                                            |     |                   |     9,002,765 |     |          |   * |   |
| Sijmen de Vries (7)                                         |     |                   |     9,000,000 |     |          |   * |   |
| Directors and senior management as a group (5 persons)  (8) |     |                   |    71,893,328 |     |          |   * |   |

________________

| * | Represents beneficial ownership of less than one percent. |

| ** | Excludes certain securities subject to a beneficial ownership blocker. See notes (1) and (2) below. |

| (1) | Based primarily on the Schedule 13G filed by Bigger Capital Fund, LP